A month or so in the past, we castigated some extraordinarily poorly reasoned skilled exclusion selections within the Bulox v. Coopersurgical litigation. The top outcomes weren’t horrible (p-side motions had been denied), however th0se Rule 702 opinions fully ignored the modifications wrought by the 2023 amendments to that Rule. It was so placing that we went on PACER to see whether or not protection counsel was accountable for any of that – they weren’t.
Nicely, as we speak we’re cheering the most recent choice(s) in the identical litigation. Bulox v. Coopersurgical, Inc., 2025 U.S. Dist. Lexis 56370 (Magazine. S.D. Tex. March 6, 2005) (“Bulox I”), adopted, 2025 U.S. Dist. Lexis 54755 (S.D. Tex. March 25, 2025) (“Bulox II”), is nearly as good a PMA medical system preemption choice as a defendant has a proper to count on. This Bulox choice ought to go a good distance in direction of defeating the opposite facet’s newest marketing campaign to deprive ladies of contraceptive alternative.
The product, Filshie clips, being FDA pre-market authorized medical units, had been coated by the in depth categorical preemption acknowledged by the Supreme Courtroom in Riegel v. Medtronic, Inc., 552 U.S. 312 (2008). Bulox I, 2025 U.S. Dist. Lexis 56370, at *2-3. Along with categorical preemption, preemption dodges masquerading as “parallel” claims had been topic to implied preemption beneath Buckman Co. v. Plaintiffs Authorized Committee, 531 U.S. 341 (2001), to the (giant) extent that they’re non-public makes an attempt to implement the FDCA. Bulox I, 2025 U.S. Dist. Lexis 56370, at *4.
The plaintiffs’ main rivalry in Filshie clip instances seems to be that the “adversarial occasions” part of this system’s FDA authorized labeling states a “migration fee of 0.13%, whereas plaintiffs declare the migration fee is nearer to 25%. There’s a superbly good motive for that, as a result of adversarial occasions must be “adversarial” and the nice majority of migrations are asymptomatic or minor, as we mentioned right here.
Plaintiffs, nevertheless, continuously try to make use of that discrepancy to assert that the defendant producer did not report adversarial occasions, and so they tried the identical ploy in Bulox. It backfired, large time. Bulox I acknowledged that these weren’t what the FDA thought of adversarial occasions in any respect:
[Defendant] reviewed the complaints however decided that the reporting threshold was not met as to any of them. In its 2019 PMA annual report, [it] reported its skilled decided that, during the last 10 years, “[n]one of many Filshie clip migrations had been life-threatening or brought about everlasting impairment of a physique perform.”
2025 U.S. Dist. Lexis 56370, at *5 (quotation omitted).
Not solely was the failure-to-report declare factually unsupported, but it surely was legally meritless as effectively. “[T]he Courtroom finds that preemption bars all Plaintiffs’ claims.” Id. at *6.
Design defect claims – Plaintiffs unsuccessfully tried to import their reporting-based rubbish into their design-related arguments. Id. at *8 (“[t]he design was authorized by the FDA with out the advantage of the information that Filshie Clips had a larger than .13% threat of migration”). That, after all, is exactly the identical fraud-on-the-FDA allegation made in Buckman. None of that helped as a result of the plaintiffs did “not plead that the Filshie Clips . . . had been designed in a fashion apart from because the FDA authorized.” Bulox I, 2025 U.S. Dist. Lexis 56370, at *8. “As a result of Plaintiffs haven’t alleged that the product in query was designed in violation of federal requirements, they’ve did not plausibly state a declare for design defect that might keep away from preemption beneath the MDA.” Id. at *9 (citations omitted). As in Buckman, plaintiffs’ try to “join” the design declare “to the adversarial occasion reporting requirement” was impliedly preempted.
[A]lthough embedded in state-law phrases, any such claims would exist solely by advantage of federal regulation. Accordingly, this Courtroom finds that, to the extent [Plaintiffs’] claims are usually not expressly preempted . . . they’re impliedly preempted.
Bulox I, 2025 U.S. Dist. Lexis 56370, at *10 (citations and citation marks omitted).
And simply to make certain, the design declare failed on state-law grounds as effectively. Plaintiffs’ purported “various designs” (required beneath Texas regulation) weren’t a design in any respect, however moderately different types of surgical procedure that didn’t contain any clips. Id. As we mentioned at size right here, completely different surgical procedures are usually not various product designs.
Right here, the proposed alternate options are surgical procedures or strategies completely different from the Filshie Clip ligation, however beneath Texas regulation, Plaintiffs should suggest a safer and possible various design to the alleged faulty designs, not completely different procedures or methods solely.
Id. at *11 (citations and citation marks omitted).
One down.
Warning defect claims − Plaintiffs warning declare was additionally preempted. It was, as regular, the bogus migration fee allegation. Id. To the extent that plaintiffs claimed that the FDA-approved fee for adversarial migration-related occasions was improper, that was “completely different from” the FDA-approved warning and expressly preempted. “Federal regulation squarely preempts any declare for failure to supply satisfactory warnings or directions that might query the sufficiency of the FDA-approved labeling, warnings, and directions.” Id. at *12. Since plaintiffs didn’t declare that the FDA-approved labeling was not on the system, they’d no warning declare. Id. at *13.
Plaintiffs additionally tried to morph their warning allegations right into a “later-acquired information idea” – that data the defendants discovered after the FDA authorized the warning required them to vary the warning. Id. That reporting-based declare was expressly preempted (no parallel declare), impliedly preempted (purely non-public FDCA enforcement), and did not state a state-law declare within the first place:
[While, u]nder federal regulation, system producers should report any incident to the FDA the place their system could have brought about or contributed to a demise or severe harm . . ., Texas regulation supplies no such parallel obligation. Certainly, beneath Texas regulation, producers owe an obligation to warn customers, not the FDA, of potential risks.
Id. at *14-15 (citations and citation marks omitted) (emphasis authentic).
Nor might the FDA qualify as a state-law “discovered middleman.”
Plaintiffs haven’t produced any Texas authority that this [warning] obligation might be discharged by informing the FDA, which signifies that Texas failure-to-warn claims impose a distinct requirement from federal regulation: warning customers or prescribing physicians as an alternative of warning the FDA. In consequence, this declare is preempted.
Id. at *15-16 (footnote omitted). The footnote is price a learn, too, because it distinguishes Hughes v. Boston Scientific Corp., 631 F.3d 762 (fifth Cir. 2011), as “based mostly . . . on now defunct Mississippi merchandise legal responsibility regulation.” Bulox I, 2025 U.S. Dist. Lexis 56370, at *16 n.7.
We additionally love the purpose that “Texas courts usually reject arguments that reporting statutes give rise to common-law causes of motion beneath Texas regulation.” Id. at *16 (citations and footnote omitted). That’s why we’ve collected all of the non-FDCA-related failure-to-report selections we might discover (for all 50 states) in our 50-state survey. Since there was no equal state-law declare, plaintiffs’ failure-to-report claims had been merely preempted makes an attempt to implement the FDCA privately:
Accordingly, as a result of there isn’t any “parallel” state requirement beneath Texas regulation, Plaintiffs’ rivalry that Defendants’ failure to warn by way of failure to report adversarial occasion complaints is just an try by non-public events to implement FDA reporting necessities, which is foreclosed beneath §337(a), as construed in Buckman.
Id. (quotation and citation marks omitted).
Thus, the plaintiffs’ failure-to-report declare was dismissed in Bulox I thrice over – as expressly preempted, impliedly preempted, and for failing to state a declare beneath Texas regulation.
That’s two – plaintiffs now not asserted any manufacturing defect declare.
Predictably, plaintiffs appealed the Justice of the Peace’s choice to the district courtroom. Not so predictably, the district courtroom wrote a substantive opinion adopting the Justice of the Peace’s opinion in full. That opinion held:
- Plaintiffs design defect declare was preempted as a result of there was no allegation that the product was “designed in violation of federal requirements.”
- Plaintiffs failure-to-report allegations didn’t create any “parallel” design declare.
- “[E]ntirely completely different procedures” are usually not various designs.
- “[N]o parallel obligation exists beneath Texas regulation to report adversarial occasions to the FDA.”
- Failure-to-report claims are “merely an try by non-public events to implement FDA reporting necessities, which is foreclosed beneath 21 U.S.C. §337(a).”
- “[T]he Courtroom agrees with [the] evaluation of the Fifth Circuit’s opinion in Hughes.”
- “Plaintiffs haven’t recognized an unbiased and parallel supply of legal responsibility in Texas regulation for violating federal reporting necessities.”
Bulox II, 2025 U.S. Dist. Lexis 54755, at *3-9 (varied citations and citation marks omitted).
Total, we predict that is the perfect choice but out of the Filshie clip liltigation.